Combination therapy shown to shrink tumours

A collaborative team effort led by the Tumor Immunotherapy and Microenvironment (TIME) group at the Luxembourg Institute of Health, along with Sprint Bioscience and Karolinska Institutet (Sweden) has discovered a promising new approach for cancer treatment. This strategy focuses on unlocking the full potential of STING agonists, a new class of drugs designed to boost the body’s immune system to fight cancer.

Cancer cells can employ various strategies to evade the body’s natural defences, rendering existing immunotherapies ineffective.  Previous research work by the TIME group and Sprint Bioscience showed how inhibiting a specific protein (Vps34) involved in this immune evasion could enhance the effectiveness of existing cancer immunotherapy based on checkpoint blockades. Building upon this success, the latest study explores the exciting synergy between Vps34 inhibitors and STING agonists.

STING agonists work by stimulating a pivotal protein known as STING, to trigger a robust response against cancer cells, mobilising and empowering diverse immune cells, including T cells, natural killer cells and dendritic cells.

The new research demonstrated that combining a Vps34 inhibitor with a STING agonist results in a potent double attack on tumours. This combination significantly shrinks tumours and improves survival rates in preclinical studies, offering a potential paradigm shift in cancer treatment.

“This research offers a new hope for overcoming the several disappointments encountered in past clinical trials with STING agonists. By enhancing the STING pathway and circumventing cancer’s immune evasion strategies, we have the potential to develop durable and powerful new immunotherapies,” said Dr Bassam Janji, Head of the TIME group.

The full study was published in Molecular Oncology

More information online